FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gilles Peytavin

Research Profile

Disorders

HIV Infections

Living Beings

HIV-1

Chemicals & Drugs

Concepts & Ideas

Physiology

Procedures

Activities & Behaviors

Patient Compliance

Co-author Network

Publications

TOP 3
David Zucman; Gilles Peytavin; L Tegna; Laurence Weiss; A Benalycherif; pierre de truchis; Jean L Delassus; Diane Descamps; C Duvivier; Roland Landman
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Minh P Lê; Kivan Long; Hervé Mal; Emmanuelle Papy; Diane Descamps; Anne Gervais; Lucile Larrouy; Christine Le Beller; Gilles Peytavin
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
C Vinot; E Courbon; Xavier Declèves; D Duro; L Gavard; S Manceau; Laurent Mandelbrot; Gilles Peytavin; J M Scherrmann; Jean-Marc Tréluyer; C Giraud
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gilles Peytavin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David Zucman; Gilles Peytavin; L Tegna; Laurence Weiss; A Benalycherif; pierre de truchis; Jean L Delassus; Diane Descamps; C Duvivier; Roland Landman
Efficacy, safety, and pharmacokinetics of once-daily boosted darunavir in pretreated HIV-infected patients.
Scandinavian journal of infectious diseases 2013;45(5):407-10.
2013: Minh P Lê; Kivan Long; Hervé Mal; Emmanuelle Papy; Diane Descamps; Anne Gervais; Lucile Larrouy; Christine Le Beller; Gilles Peytavin
Serious neuropsychiatric adverse effects in a hepatitis C virus/hepatitis B virus/HIV-coinfected patient receiving bosentan and telaprevir.
The Journal of antimicrobial chemotherapy 2013;68(5):1208-9.
2013: C Vinot; E Courbon; Xavier Declèves; D Duro; L Gavard; S Manceau; Laurent Mandelbrot; Gilles Peytavin; J M Scherrmann; Jean-Marc Tréluyer; C Giraud
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.
Antimicrobial agents and chemotherapy 2013;57(3):1415-20.
2013: Minh P Lê; Cathia Soulie; Hind Stitou; Christine Katlama; Gilles Peytavin
Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.
The Journal of antimicrobial chemotherapy 2013;68(3):727-9.
2013: Eric Ouattara; Gilles Peytavin; Franck Bohoussou; Jérome Le Carrou; Christine Danel; Jules Bashi; Delphine Gabillard; Romuald Konan; Raoul Moh; Xavier Anglaret
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Journal of the International AIDS Society 2013;16():18059.
2013: Jade Ghosn; Allal Houssaini; Christine Katlama; Sidonie Lambert-Niclot; Robert Murphy; Gilles Peytavin; Luminita Schneider; Anne Simon; Laurence Slama; Aziza Chermak; Eve Courbon; Claudine Duvivier; Philippe Flandre; Erwan Fourn
Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Journal of medical virology 2013;85(1):8-15.
2012: Lise Cuzin; Pierre Delobel; Philippe Flandre; Jade Ghosn; Caroline Lascoux-Combe; Gilles Peytavin; Christina Psomas; Jacques Reynes; Selma Trabelsi; Clotilde Allavena; Claudine Barbuat; Pierre Corbeau
Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study.
Journal of acquired immune deficiency syndromes (1999) 2012;61(5):557-64.
2012: Caroline Solas; Maria Winnock; Firouzé Bani-Sadr; Stéphanie Dominguez; Rodolphe Garraffo; Jacques Izopet; Elodie Pambrun; Gilles Peytavin; Isabelle Poizot-Martin; Dominique Salmon
Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction?
AIDS (London, England) 2012;26(17):2193-9.
2012: Minh Patrick Lê; Patrice Muret; Isabelle Poizot-Martin; Caroline Solas; Patrick Yeni; Catherine Dhiver; Jacques Durant; Marie-Claude Gagnieu; Rodolphe Garraffo; Christine Katlama; Gilles Peytavin
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
The Journal of antimicrobial chemotherapy 2012;67(11):2779-81.
2012: Sidonie Lambert-Niclot; Anne-Geneviève Marcelin; Bernard Masquelier; Brigitte Montes; Laurence Morand-Joubert; Valerie Perrot; Gilles Peytavin; Jean-Christophe Plantier; Cathia Soulie; Vincent Calvez; Sophie Carret; Charlotte Charpentier; Isabelle Cohen Codar; Dominique Costagliola; Constance Delaugerre; Virginie Ferre
Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.
The Journal of antimicrobial chemotherapy 2012;67(10):2487-93.
2012: C Clavel; E Courbon; C Crenn-Hebert; H Ichou; C Katlama; Anne-Geneviève Marcelin; Gilles Peytavin; L Schneider; Cathia Soulié; R Tubiana; C Blanc; Laurent Mandelbrot
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.
Antimicrobial agents and chemotherapy 2012;56(7):4018-20.
2012: Sidonie Lambert-Niclot; Michele Algarte-Genin; Vincent Calvez; Constance Delaugerre; Philippe Flandre; Christine Katlama; Laurence Morand-Joubert; Gilles Peytavin; Sophie Sayon; Marc-Antoine Valantin; Anne-Genevieve Marcelin
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
The Journal of antimicrobial chemotherapy 2012;67(6):1470-4.
2012: Stéphanie Dominguez; Jade Ghosn; Christine Katlama; Anne-Sophie Lascaux; Yves Lévy; Giovanna Melica; Magali Bouvier-Alias; Bruno Cassard; Isabelle Poizot-Martin; Caroline Solas; Gilles Peytavin
Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
The Journal of antimicrobial chemotherapy 2012;67(6):1449-52.
2012: Ruxandra Calin; Rachid Agher; Luc Paris; Gilles Peytavin; Luminita Schneider; Anne Simon; Roland Tubiana; Marc-Antoine Valantin; Marc Wirden; Christine Katlama
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Antiviral therapy 2012;17(8):1601-4.
2012: Hélène Lazareth; Gilles Peytavin; Laura Polivka; Nicolas Dupin
The hairy-print for levamisole-induced vasculitis.
BMJ case reports 2012;2012():.
2012: Stéphane Le Vu; Laurence Meyer; Gilles Peytavin; Josiane Pillonel; Francis Barin; Jérôme Guinard; Annie Velter; Caroline Semaille
Biomarker-based HIV incidence in a community sample of men who have sex with men in Paris, France.
PloS one 2012;7(6):e39872.
2012: Olivier Lada; Laurence Leclerc; Michel Branger; Gilles Collin; Gil Fraqueiro; Anne Gervais; Michèle Martinot-Peignoux; Sophie Matheron; Rami Moucari; Gilles Peytavin; Benedicte Roquebert; Patrick Marcellin
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Antiviral therapy 2012;17(1):61-70.
2012: Benoit Visseaux; Romain Antoine; Françoise Brun-Vézinet; Charlotte Charpentier; Florence Damond; Diane Descamps; Margarita Hurtado-Nedelec; Sophie Matheron; Gilles Peytavin; Alexandre Storto
In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Antimicrobial agents and chemotherapy 2012;56(1):137-9.
2011: Lucile Larrouy; Gilles Peytavin; Patrick Yeni; Françoise Brun Vezinet; Catherine Capitant; Charlotte Charpentier; Corine Chazallon; Florence Damond; Diane Descamps; Roland Landman
Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.
AIDS (London, England) 2011;25(17):2143-8.
2011: Sidonie Lambert-Niclot; Gilles Peytavin; Marc-Antoine Valantin; Yazdan Yazdanpanah; Michele Algarte-Genin; Vincent Calvez; Claudine Duvivier; Philippe Flandre; Pierre-Marie Girard; Stephanie Haim-Boukobza; Christine Katlama; Anne-Genevieve Marcelin
Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.
The Journal of infectious diseases 2011;204(8):1211-6.
2011: Sidonie Lambert-Niclot; Manuela Bonmarchand; Vincent Calvez; Stephanie Dominguez; Philippe Flandre; Allal Houssaini; Gilles Peytavin; Catherine Poirot; Marie Prades; Benoit Schubert; Cathia Soulié; Roland Tubiana; Anne-Geneviève Marcelin
Effect of antiretroviral drugs on the quality of semen.
Journal of medical virology 2011;83(8):1391-4.
2011: Laurent Mandelbrot; Fabienne Mazy; Françoise Meier; Elie Azria; Catherine Crenn-Hebert; Claudia Ferreira; Corinne Floch-Tudal; Evelyne Herinomenzanahary; Jean-Marc Treluyer; Gilles Peytavin
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
European journal of obstetrics, gynecology, and reproductive biology 2011;157(1):18-21.
2011: Saïk Urien; Suzanne T Anderson; Stéphane Blanche; Albert Faye; Ghislaine Firtion; Carole Giraud; Déborah Hirt; Saye Khoo; Marthe Leprevost; Hermione Lyall; Gilles Peytavin; Caroline Solas; Isabelle Thuret; Jean-Marc Tréluyer
Lopinavir/ritonavir population pharmacokinetics in neonates and infants.
British journal of clinical pharmacology 2011;71(6):956-60.
2011: Cyril Clavel; Gilles Peytavin; Roland Tubiana; Cathia Soulié; Catherine Crenn-Hebert; Isabelle Heard; François Bissuel; Houria Ichou; Claudia Ferreira; Christine Katlama; Anne-Geneviève Marcelin; Laurent Mandelbrot
Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study).
Antimicrobial agents and chemotherapy 2011;55(6):3018-21.
2011: Charlotte Charpentier; Françoise Brun-Vézinet; Vincent Calvez; Mathieu Felices; Christine Katlama; Sidonie Lambert-Niclot; Roland Landman; Lucile Larrouy; Anne-Geneviève Marcelin; Gilles Peytavin; Marc-Antoine Valantin; Patrick Yeni; Diane Descamps
Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score.
Journal of acquired immune deficiency syndromes (1999) 2011;57(1):e15-7.
2011: JJ Parienti; Gilles Peytavin
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
Expert opinion on drug metabolism & toxicology 2011;7(4):495-503.
2011: Céline Eiden; Hélène Peyriere; Gilles Peytavin; Jacques Reynes
Severe insomnia related to high concentrations of raltegravir.
AIDS (London, England) 2011;25(5):725-7.
2011: Charlotte Charpentier; Pantxika Bellecave; Mohamed Cisse; Saidou Mamadou; Mandiou Diakite; Gilles Peytavin; Stéphanie Tchiombiano; Pierre Teisseire; Louis Pizarro; Alexandre Storto; Françoise Brun-Vézinet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin; Bernard Masquelier; Diane Descamps
High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
Antiviral therapy 2011;16(3):429-33.
2011: Violaine Ozenne; A Gervais; Gilles Peytavin; Corinne Castelnau; Dominique-Charles Valla; Françoise Degos
Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report.
Hepato-gastroenterology 2011;58(105):161-2.
2010: Stephanie Dominguez; Jade Ghosn; Gilles Peytavin; Marguerite Guiguet; Roland Tubiana; Marc-Antoine Valantin; Robert Murphy; François Bricaire; Yves Benhamou; Christine Katlama
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
The Journal of antimicrobial chemotherapy 2010;65(11):2445-9.
2010: Sidonie Lambert-Niclot; Gilles Peytavin; Claudine Duvivier; Catherine Poirot; Michèle Algarte-Genin; Sophie Pakianather; Jean-Luc Meynard; Marc-Antoine Valantin; Jean-Michel Molina; Philippe Flandre; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy.
Antimicrobial agents and chemotherapy 2010;54(11):4910-3.
2010: Christine Katlama; Marc-Antoine Valantin; Michele Algarte-Genin; Claudine Duvivier; Sidonie Lambert-Niclot; Pierre M Girard; Jean M Molina; Bruno Hoen; Sophie Pakianather; Gilles Peytavin; Anne-Geneviève Marcelin; Philippe Flandre
Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
AIDS (London, England) 2010;24(15):2365-74.
2010: Aude Desnoyer; Firas Al Kaied; Diane Descamps; Patrick Yeni; Vincent Descamps; Christine Le Beller; Gilles Peytavin
Deleterious pharmacokinetic interaction between bexarotene and efavirenz.
AIDS (London, England) 2010;24(14):2296-8.
2010: Giovanna Melica; Ana Canestri; Gilles Peytavin; Jean D Lelievre; Magali Bouvier-Alias; Cyril Clavel; Vincent Calvez; Anne S Lascaux; Christine Katlama; Yves Levy
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
AIDS (London, England) 2010;24(13):2130-3.
2010: Lucile Larrouy; C Chazallon; R Landman; C Capitant; Gilles Peytavin; G Collin; C Charpentier; A Storto; G Pialoux; Christine Katlama; P M Girard; Patrick Yeni; J P Aboulker; F Brun-Vezinet; D Descamps
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Antimicrobial agents and chemotherapy 2010;54(7):2910-9.
2010: Fabienne Caby; Nadia Valin; Anne Genevieve Marcelin; Luminata Schneider; Régis Andrade; Marguerite Guiguet; Roland Tubiana; Ana Canestri; Marc-Antoine Valantin; Gilles Peytavin; Jérome Pacanowski; Laurence Morand-Joubert; Vincent Calvez; Pierre Marie Girard; Christine Katlama
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Scandinavian journal of infectious diseases 2010;42(6-7):527-32.
2010: JJ Parienti; Gilles Peytavin; Véronique Reliquet; Renaud Verdon; Antoine Coquerel
Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(11):1547-8.
2010: Roland Landman; M B Diallo; N F Ngom Gueye; Coumba Touré Kane; Souleymane MBoup; M B Koita Fall; Bassirou Ndiaye; Gilles Peytavin; Y Bennai; A Benalycherif; Pierre-Marie Girard; Papa Salif Sow
Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
AIDS research and human retroviruses 2010;26(5):519-25.
2010: Hassane Izzedine; Vincent Thibault; Marc-Antoine Valantin; Gilles Peytavin; Luminita Schneider; Yves Benhamou
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
AIDS (London, England) 2010;24(7):1078-9.
2010: Ana Canestri; François-Xavier Lescure; Stephane Jaureguiberry; Antoine Moulignier; Corinne Amiel; Anne-Geneviève Marcelin; Gilles Peytavin; Roland Tubiana; Gilles Pialoux; Christine Katlama
Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50(5):773-8.
2010: Constance Delaugerre; J F Buyck; Gilles Peytavin; J P Viard; M L Chaix; D Zucman; E Mortier; S Blanche; E Rouveix; G Force; P Aegerter; pierre de truchis
Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2010;47(3):248-52.
2010: Elisabeth Aslangul; Lambert Assoumou; Randa Bittar; Marc-Antoine Valantin; Olga Kalmykova; Gilles Peytavin; Marie-Hélène Fiévet; Franck Boccara; Dominique Bonnefont-Rousselot; Jean-Claude Melchior; Philippe Giral; Dominique Costagliola
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
AIDS (London, England) 2010;24(1):77-83.
2009: Laurent Gavard; Delphine Beghin; François Forestier; Yvon Cayre; Gilles Peytavin; Laurent Mandelbrot; Robert Farinotti; Sophie Gil
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.
European journal of obstetrics, gynecology, and reproductive biology 2009;147(2):157-60.
2009: Constance Delaugerre; Blandine Denis; Gilles Peytavin; Pierre Palmer; Thomas Mourez; Jerôme Le Goff; Jean-Michel Molina; François SIMON
Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient.
Journal of clinical microbiology 2009;47(11):3763-4.
2009: Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Isabelle Malet; Hocine Ait Mohand; Gilles Peytavin; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
The Journal of antimicrobial chemotherapy 2009;64(5):1087-90.
2009: Xavier Duval; France Mentré; Elisabeth Rey; Solange Auleley; Gilles Peytavin; Michel Biour; Annie Métro; Cécile Goujard; Anne-Marie Taburet; Cecile Lascoux; Xavière Panhard; Jean-Marc Tréluyer; Dominique Salmon-Céron
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial.
Fundamental & clinical pharmacology 2009;23(4):491-500.
2009: Jade Ghosn; Anne-Aurélie Mazet; Véronique Avettand-Fenoel; Gilles Peytavin; Marc Wirden; Jean-François Delfraissy; Marie-Laure Chaix
Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
The Journal of antimicrobial chemotherapy 2009;64(2):433-4.
2009: Cathia Soulié; Lambert Assoumou; Jade Ghosn; Claudine Duvivier; Gilles Peytavin; Zaina Ait-Arkoub; Jean-Michel Molina; Dominique Costagliola; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
AIDS (London, England) 2009;23(12):1605-8.
2009: Roland Landman; Catherine Capitant; Diane Descamps; Corine Chazallon; Gilles Peytavin; Christine Katlama; Gilles Pialoux; Michelle Bentata; Françoise Brun-Vézinet; Jean-Pierre Aboulker; Patrick Yéni
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
The Journal of antimicrobial chemotherapy 2009;64(1):118-25.
2009: Antoine Bénard; Florence Damond; Pauline Campa; Gilles Peytavin; Diane Descamps; Caroline Lascoux-Combes; Audrey Taieb; François SIMON; Brigitte Autran; Françoise Brun-Vézinet; Geneviève Chêne; sophie matheron
Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
AIDS (London, England) 2009;23(9):1171-3.
2009: Isabelle Malet; Olivier Delelis; Cathia Soulie; Marc Wirden; Luba Tchertanov; Philippe Mottaz; Gilles Peytavin; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Geneviève Marcelin
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 2009;63(4):795-804.
2009: Diane Descamps; Sidonie Lambert-Niclot; Anne-Geneviève Marcelin; Gilles Peytavin; Bénédicte Roquebert; Christine Katlama; Patrick Yeni; Mathieu Felices; Vincent Calvez; Françoise Brun-Vézinet
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
The Journal of antimicrobial chemotherapy 2009;63(3):585-92.
2009: David Rey; Bruno Hoen; P Chavanet; Marie-Paule Schmitt; G Hoizey; P Meyer; Gilles Peytavin; B Spire; Clotilde Allavena; M Diemer; T May; J L Schmit; M Duong; Vincent Calvez; Jean-Marie Lang
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 2009;63(2):380-8.
2009: Alice Breining; Francois Bricaire; Ana Canestri; Amélie Guihot; Gilles Peytavin; Dominique Warot; Eric Caumes
Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapy.
BMJ case reports 2009;2009():.
2009: Gilles Peytavin; Vincent Calvez; Christine Katlama
[CCR5 antagonists: a new class of antiretrovirals].
Thérapie 2009;64(1):9-16.
2009: Matthijs van Luin; Wendy P Bannister; Amanda Mocroft; Peter Reiss; Giovanni Di Perri; Gilles Peytavin; José Molto; Anders Karlson; Antonella Castagna; Marek Beniowski; Jens D Lundgren; David Burger
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
Antiviral therapy 2009;14(1):75-83.
2008: Bénédicte Roquebert; Laurent Blum; Gilles Collin; Florence Damond; Gilles Peytavin; Juliette Leleu; sophie matheron; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
AIDS (London, England) 2008;22(15):2045-6.
2008: H Ait-Mohand; M Bonmarchand; M Guiguet; L Slama; F Marguet; A Behin; B Amellal; Y Bennai; Gilles Peytavin; Vincent Calvez; Gilles Pialoux; R Murphy; Christine Katlama
Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study.
HIV medicine 2008;9(9):738-46.
2008: Claudine Duvivier; Jade Ghosn; Lambert Assoumou; Cathia Soulié; Gilles Peytavin; Vincent Calvez; Michèle Algarté Génin; Jean-Michel Molina; Olivier Bouchaud; Christine Katlama; Dominique Costagliola
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
The Journal of antimicrobial chemotherapy 2008;62(4):797-808.
2008: Marc-Antoine Valantin; Emilie Lanoy; Michelle Bentata; O Kalmykova; A Boutekadjirt; Clotilde Allavena; Willy Rozenbaum; Gilles Peytavin; Bahia Amellal; Vincent Calvez; Dominique Costagliola; Christine Katlama
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
HIV medicine 2008;9(8):625-35.
2008: Anne-Geneviève Marcelin; Bernard Masquelier; Diane Descamps; Jacques Izopet; Charlotte Charpentier; Chakib Alloui; Magali Bouvier-Alias; Anne Signori-Schmuck; Brigitte Montes; Marie-Laure Chaix; Corinne Amiel; Georges Dos Santos; Annick Ruffault; Francis Barin; Gilles Peytavin; Marc Lavignon; Philippe Flandre; Vincent Calvez
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2008;52(9):3237-43.
2008: Diane Descamps; Lambert Assoumou; Bernard Masquelier; Anne-Geneviève Marcelin; Souhila Saidi; Catherine Tamalet; Jacqueline Cottalorda; Jean-Christophe Plantier; Brigitte Montes; Jacques Izopet; Gilles Peytavin; Sabine Yerly; Véronique Schneider; Constance Delaugerre; Virginie Ferré; Annick Ruffault; Coralie Pallier; Laurence Morand-Joubert; Marie-Laure Chaix; Vincent Calvez; Françoise Brun-Vézinet; Dominique Costagliola
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
The Journal of antimicrobial chemotherapy 2008;62(3):451-5.
2008: Anne-Geneviève Marcelin; Roland Tubiana; Sidonie Lambert-Niclot; Gilles Lefebvre; Stéphanie Dominguez; Manuela Bonmarchand; Daniele Vauthier-Brouzes; Françoise Marguet; Nathalie Mousset-Simeon; Gilles Peytavin; Catherine Poirot
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
AIDS (London, England) 2008;22(13):1677-9.
2008: Charles Kouanfack; Christian Laurent; Gilles Peytavin; Laura Ciaffi; Maguy Ngolle; Yvette Mawamba Nkene; Claudine Essomba; Alexandra Calmy; Eitel Mpoudi-Ngolé; Eric Delaporte; Sinata Koulla-Shiro
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
Journal of acquired immune deficiency syndromes (1999) 2008;48(2):216-9.
2008: Jade Ghosn; Marie-Laure Chaix; Gilles Peytavin; Jean-Louis Bresson; Julie Galimand; Pierre-Marie Girard; François Raffi; Isabelle Cohen-Codar; Jean-François Delfraissy; Christine Rouzioux
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
The Journal of antimicrobial chemotherapy 2008;61(6):1344-7.
2008: Jade Ghosn; Ines De Montgolfier; Chantal Cornélie; Stephanie Dominguez; Claire Pérot; Gilles Peytavin; Anne-Geneviève Marcelin; Michèle Pauchard; Zineb Ouagari; Manuela Bonmarchand; Rachid Agher; Vincent Calvez; François Bricaire; Marc Dommergues; Christine Katlama; Roland Tubiana
Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.
Antimicrobial agents and chemotherapy 2008;52(4):1542-4.
2008: Pierre Francois CECCALDI; Claudia Ferreira; Laurent Gavard; Sophie Gil; Gilles Peytavin; Laurent Mandelbrot
Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.
American journal of obstetrics and gynecology 2008;198(4):433.e1-2.
2008: Delphine Desbois; Bénédicte Roquebert; Gilles Peytavin; Florence Damond; Gilles Collin; Antoine Bénard; Pauline Campa; Sophie Matheron; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Antimicrobial agents and chemotherapy 2008;52(4):1545-8.
2008: Isabelle Malet; Olivier Delelis; Marc-Antoine Valantin; Brigitte Montes; Cathia Soulie; Marc Wirden; Luba Tchertanov; Gilles Peytavin; Jacques Reynes; Jean-François Mouscadet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrobial agents and chemotherapy 2008;52(4):1351-8.
2008: Florence Damond; Sylvie Lariven; Benedicte Roquebert; Sylvia Males; Gilles Peytavin; Genevieve Morau; Daniel Toledano; Diane Descamps; Françoise Brun Vezinet; Sophie Matheron
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
AIDS (London, England) 2008;22(5):665-6.
2008: Sidonie Lambert-Niclot; Philippe Flandre; Ana Canestri; Gilles Peytavin; Christine Blanc; Rachid Agher; Cathia Soulié; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Antimicrobial agents and chemotherapy 2008;52(2):491-6.
2007: Anne-Geneviève Marcelin; Bernard Jarrousse; Anne Derache; Madina Ba; Marie-Léa Dakouo; Alioune Doumbia; Ibrahima Haidara; Almoustapha Maïga; Guislaine Carcelain; Gilles Peytavin; Christine Katlama; Vincent Calvez
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
AIDS (London, England) 2007;21(17):2341-3.
2007: Marie Essig; Xavier Duval; Firas Al Kaied; Laura Iordache; Anne Gervais; Pascale Longuet; Francoise Blanchet; Gilles Peytavin; Catherine Leport
Is phosphatemia the best tool to monitor renal tenofovir toxicity?
Journal of acquired immune deficiency syndromes (1999) 2007;46(2):256-8.
2007: Ana Canestri; Mamadou Cisse; Anne-Geneviève Marcelin; Gilles Peytavin; Emmanuel Traore; Lambert Assoumou; Ousmane Traore; Victoria Koita; Fodie Diallo; Awa Thiero Sangare; Mayrama Koita Sidibé; Vincent Calvez; Aliou Sylla; Christine Katlama; Roland Tubiana
Experience of indinavir/ritonavir 400/100 mg twice-daily highly active antiretroviral therapy-containing regimen in HIV-1-infected patients in Bamako, Mali: the NOGOMA Study.
Journal of acquired immune deficiency syndromes (1999) 2007;45(4):477-9.
2007: Constance Delaugerre; Dominique Mathez; Gilles Peytavin; Huguette Berthé; Kivan Long; Tatiana Galperine; pierre de truchis
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
AIDS (London, England) 2007;21(9):1210-3.
2007: Fidéline Collin; Geneviève Chêne; Sylvie Retout; Gilles Peytavin; Dominique Salmon; Elisabeth Bouvet; François Raffi; Rodolphe Garraffo; France Mentré; Xavier Duval
Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults.
Therapeutic drug monitoring 2007;29(2):164-70.
2007: Christian Laurent; Charles Kouanfack; Sinata Koulla-Shiro; Maguy Njoume; Yvette Mawamba Nkene; Laura Ciaffi; Charlotte Brulet; Gilles Peytavin; Laurence Vergne; Alexandra Calmy; Eitel Mpoudi-Ngolé; Eric Delaporte
Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
AIDS (London, England) 2007;21(6):768-71.
2007: Marie-Laure Chaix; Didier K Ekouevi; Gilles Peytavin; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Clarisse Amani-Bosse; Hervé Menan; Valériane Leroy; Christine Rouzioux; François Dabis
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
Antimicrobial agents and chemotherapy 2007;51(3):896-901.
2007: Stephanie Dominguez; Jade Ghosn; Gilles Peytavin; Hassane Izzedine; Marc Wirden; Nadine Ktorza; M Miller; Camille Aubron-Olivier; Aldo Trylesinski; Vincent Calvez; Gilbert Deray; Christine Katlama
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Journal of medical virology 2007;79(2):105-10.
2007: Xavier Duval; Gilles Peytavin; Guillaume Breton; Jean-Luc Ecobichon; Diane Descamps; Gabriel Thabut; Catherine Leport
Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination.
AIDS (London, England) 2007;21(1):106-8.
2007: Ana Canestri; Eric Delaporte; Pierre Marie Girard; Mandoumbé Gueye; Coumba Touré Kane; Roland Landman; Souleymane M'Boup; Fatou Ngom; Gilles Peytavin; Papa Salif Sow; Muriel Vray
Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.
Journal of the International AIDS Society 2007;9(4):7.
2007: Anna Canestri; Papa Salif Sow; Muriel Vray; Fatou Ngom; Souleymane M'Boup; Coumba Toure Kane; Eric Delaporte; Mandoumé Gueye; Gilles Peytavin; Pierre-Marie Girard; Roland Landman
Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
MedGenMed : Medscape general medicine 2007;9(4):7.
2007: Anissa Igoudjil; Adjé Abbey-Toby; Karima Begriche; Alain Grodet; Karine Chataigner; Gilles Peytavin; Mustapha Maachi; Marion Colin; Marie-Anne Robin; Philippe Lettéron; Gérard Feldmann; Dominique Pessayre; Bernard Fromenty
High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice.
Antiviral therapy 2007;12(3):389-400.
2007: Anne-Geneviève Marcelin; Philippe Flandre; Carmen de Mendoza; Bénédicte Roquebert; Gilles Peytavin; Luisa Valer; Marc Wirden; Sarah Abbas; Christine Katlama; Vincent Soriano; Vincent Calvez
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Antiviral therapy 2007;12(2):247-52.
2007: Christine Danel; Raoul Moh; Gilles Peytavin; Amani Anzian; Albert Minga; Olivier Ba Gomis; Boga Seri; Gustave Nzunettu; Delphine Gabillard; Roger Salamon; Emmanuel Bissagnene; Xavier Anglaret
Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
AIDS research and human retroviruses 2007;23(1):62-6.
2006: Christine Danel; Gilles Peytavin; Raoul Moh; Romuald Konan; Delphine Gabillard; Xavier Anglaret
Stability of ritonavir soft capsule formulation in patients with and without a refrigerator at home in Côte d'Ivoire.
International journal of STD & AIDS 2006;17(11):784-5.
2006: Laurent Gavard; Sophie Gil; Gilles Peytavin; Pierre Francois CECCALDI; Claudia Ferreira; Robert Farinotti; Laurent Mandelbrot
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model.
American journal of obstetrics and gynecology 2006;195(1):296-301.
2006: Alain Makinson; Bernard Masquelier; Audrey Taieb; Gilles Peytavin; Anne Waldner-Combernoux; Gilles Collin; Geneviève Chêne; Françoise Brun-Vézinet; François Raffi; Vincent Le Moing; Catherine Leport; Diane Descamps
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART.
AIDS (London, England) 2006;20(9):1327-9.
2006: Marie-Laure Chaix; Didier K Ekouevi; François Rouet; Besigin Tonwe-Gold; Ida Viho; Laurence Bequet; Gilles Peytavin; Hassane Toure; Hervé Menan; Valériane Leroy; François Dabis; Christine Rouzioux
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
The Journal of infectious diseases 2006;193(4):482-7.
2006: Sophie Matheron; Florence Damond; Antoine Benard; Audrey Taieb; Pauline Campa; Gilles Peytavin; Sophie Pueyo; Françoise Brun Vezinet; Geneviève Chene
CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.
AIDS (London, England) 2006;20(3):459-62.
2006: Cécile Loichot; Danièle Bentue-Ferrer; Nicole Bernard; Andrée Bonardet; Roselyne Boulieu; Marie-France Kergueris; Gilles Paintaud; Gilles Peytavin; Nicolas Simon; Pierre Marquet
Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
Fundamental & clinical pharmacology 2006;20(1):91-6.
2006: Bénédicte Roquebert; Isabelle Malet; Marc Wirden; Roland Tubiana; Marc-Antoine Valantin; Anne Simon; Christine Katlama; Gilles Peytavin; Vincent Calvez; Anne-Geneviève Marcelin
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
AIDS (London, England) 2006;20(2):287-9.
2006: Samir Vora; Anne-Geneviève Marcelin; Huldrych Günthard; Philippe Flandre; Hans Hirsch; Bernard Masquelier; Annelies Zinkernagel; Gilles Peytavin; Vincent Calvez; Luc Perrin; Sabine Yerly
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
AIDS (London, England) 2006;20(1):35-40.
2006: Odile Launay; Xavier Duval; Cécile Dalban; Diane Descamps; Gilles Peytavin; Agnès Certain; Saïd Mouajjah; Pascal Ralaimazava; Renaud Verdon; Dominique Costagliola; François Clavel
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Antiviral therapy 2006;11(7):889-99.
2005: Céline Verstuyft; Fabienne Marcellin; Laurence Morand-Joubert; Odile Launay; Karl Brendel; France Mentré; Gilles Peytavin; Laurence Gérard; Laurent Becquemont; Jean-Pierre Aboulker
Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.
AIDS (London, England) 2005;19(18):2127-31.
2005: Roland Landman; Diane Descamps; Gilles Peytavin; Aldo Trylesinski; Christine Katlama; Pierre-Marie Girard; B Bonnet; Patrick Yeni; Michelle Bentata; Christian Michelet; A Benalycherif; Françoise Brun Vezinet; M D Miller; Philippe Flandre
Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study.
HIV clinical trials 2005;6(6):291-301.
2005: Constance Delaugerre; Gilles Peytavin; Stephanie Dominguez; Anne-Geneviève Marcelin; Claudine Duvivier; Karine Gourlain; Bahia Amellal; Mayeule Legrand; François Raffi; Dominique Costagliola; Christine Katlama; Vincent Calvez
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
Journal of medical virology 2005;77(3):345-50.
2005: Jade Ghosn; Marc Wirden; Nadine Ktorza; Gilles Peytavin; Hocine Aït-Mohand; Luminita Schneider; Stephanie Dominguez; François Bricaire; Vincent Calvez; Dominique Costagliola; Christine Katlama
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
AIDS (London, England) 2005;19(15):1643-7.
2005: Anne-Geneviève Marcelin; Philippe Flandre; Gilles Peytavin; Vincent Calvez
Predictors of virologic response to ritonavir-boosted protease inhibitors.
AIDS reviews 2005;7(4):225-32.
2005: Christophe Delaunay; Françoise Brun-Vézinet; Roland Landman; Gilles Collin; Gilles Peytavin; Aldo Trylesinski; Philippe Flandre; M Miller; Diane Descamps
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Journal of virology 2005;79(15):9572-8.
2005: Valérie Martinez; Anne-Geneviève Marcelin; Jean-Pierre Morini; Jean Deleuze; Anne Krivine; Isabelle Gorin; Sabine Yerly; Luc Perrin; Gilles Peytavin; Vincent Calvez; Nicolas Dupin
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
AIDS (London, England) 2005;19(10):1065-9.
2005: Diane Descamps; Véronique Joly; Philippe Flandre; Gilles Peytavin; Vincent Meiffrédy; Séverine Delarue; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yeni; Françoise Brun-Vézinet
Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(2):99-103.
2005: Anne-Geneviève Marcelin; Isabelle Cohen-Codar; Martin S King; Philippe Colson; Emmanuel Guillevic; Diane Descamps; Claire Lamotte; Véronique Schneider; Jacques Ritter; MICHEL SEGONDY; Hélène Peigue-Lafeuille; Laurence Morand-Joubert; Anne Schmuck; Annick Ruffault; Pierre Palmer; Marie-Laure Chaix; Vincent Mackiewicz; Véronique Brodard; Jacques Izopet; Jacqueline Cottalorda; Evelyne Kohli; Jean-Pierre Chauvin; Dale J Kempf; Gilles Peytavin; Vincent Calvez
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2005;49(5):1720-6.
2005: Bernard Masquelier; Edwige Pereira; Gilles Peytavin; Diane Descamps; Jacques Reynes; Renaud Verdon; Hervé Fleury; R Garraffo; Geneviève Chêne; François Raffi; Françoise Brun-Vézinet
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;33(1):75-8.
2005: Hassane Izzedine; Vincent Launay-Vacher; Gilles Peytavin; Marc-Antoine Valantin; Gilbert Deray
Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(4):852-3.
2005: Michel Duong; Marielle Buisson; Gilles Peytavin; Evelyne Kohli; Lionel Piroth; Benoit Martha; Michèle Grappin; Pascal Chavanet; Henri Portier
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
The Annals of pharmacotherapy 2005;39(4):603-9.
2005: Constance Delaugerre; Laurent Roudiere; Gilles Peytavin; Christine Rouzioux; Jean-Paul Viard; Marie-Laure Chaix
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2005;32(3):241-4.
2005: Xavier Duval; France Mentré; Claire Lamotte; Geneviève Chêne; Bruno Spire; Pierre Dellamonica; Xavière Panhard; Dominique Salmon; François Raffi; Gilles Peytavin; Catherine Leport
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.
Therapeutic drug monitoring 2005;27(1):63-70.
2005: Cécile Goujard; Mayeule Legrand; Xavière Panhard; Bertrand Diquet; Xavier Duval; Gilles Peytavin; Isabelle Vincent; Christine Katlama; Catherine Leport; Bénédicte Bonnet; Dominique Salmon-Céron; France Mentré; Anne-Marie Taburet
High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Clinical pharmacokinetics 2005;44(12):1267-78.
2005: Florence Damond; Gilles Collin; Sophie Matheron; Gilles Peytavin; Pauline Campa; Séverine Delarue; Audrey Taieb; Antoine Bénard; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
Antiviral therapy 2005;10(7):861-5.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Antiviral therapy 2005;10(4):469-77.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Antiviral therapy 2005;10(3):375-92.
2005: Xavier Duval; Diane Descamps; Guillaume Breton; Sophie Darmon; Jean-Luc Ecobichon; Séverine Delarue; Gilles Peytavin; Catherine Leport; Jean-Louis Vildé; Françoise Brun-Vézinet
Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia.
Antiviral therapy 2005;10(1):197-9.
2005: Florence Damond; Françoise Brun Vezinet; Sophie Matheron; Gilles Peytavin; Pauline Campa; Sophie Pueyo; Fabrizio Mammano; STEPHANE LASTERE; Isabelle Farfara; François SIMON; Geneviève Chene; Diane Descamps
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
Journal of clinical microbiology 2005;43(1):484-7.
2004: Anne-Geneviève Marcelin; Cécile Dalban; Gilles Peytavin; Claire Lamotte; Rachid Agher; Constance Delaugerre; Marc Wirden; Françoise Conan; Sylvie Dantin; Christine Katlama; Dominique Costagliola; Vincent Calvez
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2004;48(12):4687-92.
2004: Jade Ghosn; Marie-Laure Chaix; Gilles Peytavin; Elisabeth Rey; Jean-Louis Bresson; Cécile Goujard; Christine Katlama; Jean-Paul Viard; Jean-Marc Tréluyer; Christine Rouzioux
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
AIDS (London, England) 2004;18(14):1958-61.
2004: Philippe Bossi; Gilles Peytavin; Hocine Ait Mohand; Constance Delaugerre; Nadine Ktorza; Luc Paris; Manuela Bonmarchand; R Cacace; D-J David; Anne Simon; Claire Lamotte; Anne-Geneviève Marcelin; Vincent Calvez; François Bricaire; Dominique Costagliola; Christine Katlama
GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
HIV medicine 2004;5(5):352-9.
2004: Anne-Geneviève Marcelin; Dissou Affolabi; Claire Lamotte; Hocine Ait Mohand; Constance Delaugerre; Marc Wirden; Delphine Voujon; Philippe Bossi; Nadine Ktorza; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Journal of medical virology 2004;74(1):16-20.
2004: Florence Damond; Sophie Matheron; Gilles Peytavin; Pauline Campa; Audrey Taieb; Gilles Collin; Christophe Delaunay; Geneviève Chêne; Françoise Brun-Vézinet; Diane Descamps
Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.
Antiviral therapy 2004;9(4):635-6.
2004: Christian Laurent; Charles Kouanfack; Sinata Koulla-Shiro; Nathalie Nkoué; Anke Bourgeois; Alexandra Calmy; Bernadette Lactuock; Viviane Nzeusseu; Rose Mougnutou; Gilles Peytavin; Florian Liegeois; Eric Nerrienet; Michèle Tardy; Martine Peeters; Isabelle Andrieux-Meyer; Leopold Zekeng; Michel D Kazatchkine; Eitel Mpoudi-Ngolé; Eric Delaporte
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Lancet 2004;364(9428):29-34.
2004: Michel Duong; Anne Golzi; Gilles Peytavin; Lionel Piroth; Marie Froidure; Michèle Grappin; Marielle Buisson; Evelyne Kohli; Pascal Chavanet; Henri Portier
Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice.
HIV clinical trials 2004;5(4):216-23.
2004: Xavier Duval; Gilles Peytavin; I Albert; S Bénoliel; Jean-Luc Ecobichon; Françoise Brun-Vézinet; France Mentré; Catherine Leport; Jean-Louis Vildé
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.
HIV medicine 2004;5(4):307-13.
2004: Marc Wirden; Anne-Geneviève Marcelin; Roland Tubiana; Marc-Antoine Valantin; Jade Ghosn; Claudine Duvivier; Stephanie Dominguez; Luc Paris; Rachid Agher; Gilles Peytavin; Christine Katlama; Vincent Calvez
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Journal of acquired immune deficiency syndromes (1999) 2004;36(3):876-8.
2004: Bernard Masquelier; Catherine Tamalet; Brigitte Montès; Diane Descamps; Gilles Peytavin; Laurence Bocket; Marc Wirden; Jacques Izopet; Véronique Schneider; Virginie Ferré; Annick Ruffault; Pierre Palmer; Aldo Trylesinski; M Miller; Françoise Brun-Vézinet; Dominique Costagliola
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Antiviral therapy 2004;9(3):315-23.
2004: Claire Lamotte; Roland Landman; Gilles Peytavin; France Mentre; Juliette Gerbe; Françoise Brun Vezinet; François Boue; Gabriella Spiridon; Marc-Antoine Valantin; Christian Michelet; Robert Farinotti; Patrick Yeni
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
Antiviral therapy 2004;9(2):247-56.
2004: Christine Katlama; Stephanie Dominguez; Karine Gourlain; Claudine Duvivier; Constance Delaugerre; Mayeule Legrand; Roland Tubiana; Jacques Reynes; Jean-Michel Molina; Gilles Peytavin; Vincent Calvez; Dominique Costagliola
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097).
AIDS (London, England) 2004;18(2):217-26.
2004: Guillaume Breton; Marina Alexandre; Xavier Duval; Dominique Prie; Gilles Peytavin; Catherine Leport; Jean-Louis Vildei
Tubulopathy consecutive to tenofovir-containing antiretroviral therapy in two patients infected with human immunodeficiency virus-1.
Scandinavian journal of infectious diseases 2004;36(6-7):527-8.
2004: Véronique Joly; Diane Descamps; Gilles Peytavin; Fatiha Touati; France Mentre; Xavier Duval; Séverine Delarue; Patrick Yeni; Françoise Brun Vezinet
Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs.
Antimicrobial agents and chemotherapy 2004;48(1):172-5.
2003: Vincent Le Moing; Gilles Peytavin; Valérie Journot; Jacqueline Cottalorda; Elizabeth Bouvet; Geneviève Chêne; Marie Préau; Corinne Merle De Boever; Catherine Leport; François Raffi
Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2003;34(5):497-9.
2003: Claudine Duvivier; Astriti Myrto; Anne-Geneviève Marcelin; Jade Ghosn; Hocine Ait Mohand; Luminita Schneider; Rachid Agher; François Bricaire; Dominique Costagliola; Vincent Calvez; Gilles Peytavin; Christine Katlama
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Antiviral therapy 2003;8(6):603-9.
2003: Reine Note; Caroline Maisonneuve; Philippe Lettéron; Gilles Peytavin; Fatima Djouadi; Anissa Igoudjil; Marie-Christine Guimont; Michel Biour; Dominique Pessayre; Bernard Fromenty
Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments.
Antimicrobial agents and chemotherapy 2003;47(11):3384-92.
2003: Muriel Vray; Jean-Luc Meynard; Cécile Dalban; Laurence Morand-Joubert; François Clavel; Françoise Brun-Vézinet; Gilles Peytavin; Dominique Costagliola; Pierre-Marie Girard
Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
Antiviral therapy 2003;8(5):427-34.
2003: Françoise Brun-Vézinet; Diane Descamps; Annick Ruffault; Bernard Masquelier; Vincent Calvez; Gilles Peytavin; Fabienne Telles; Laurence Morand-Joubert; Jean-Luc Meynard; Muriel Vray; Dominique Costagliola
Clinically relevant interpretation of genotype for resistance to abacavir.
AIDS (London, England) 2003;17(12):1795-802.
2003: Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Luc Paris; Anne-Geneviève Marcelin; Constance Delaugerre; Mayeule Legrand; Serge Herson; Gilles Peytavin; Christine Katlama; Vincent Calvez
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Journal of clinical microbiology 2003;41(6):2713-5.
2003: Philippe Bossi; Gilles Peytavin; Claire Lamotte; Vincent Calvez; François Bricaire; Dominique Costagliola; Christine Katlama
High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100 mg twice a day) plus two nucleoside reverse transcriptase inhibitors.
AIDS (London, England) 2003;17(7):1108-10.
2003: Ségolène Duran; Gilles Peytavin; Patrizia Carrieri; François Raffi; Jean-Luc Ecobichon; Edwige Pereira; Gilles Patrice Cassuto; Bruno Spire; Catherine Leport
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.
AIDS (London, England) 2003;17(7):1096-9.
2003: Roland Landman; Ricarda Schiemann; Safiatou Thiam; Muriel Vray; Ana Canestri; Souleymane MBoup; Coumba Touré Kane; Eric Delaporte; Papa Salif Sow; Mame Awa Faye; Mandoumbé Gueye; Gilles Peytavin; Cécile Dalban; Pierre-Marie Girard; Ibrahima Ndoye
Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal.
AIDS (London, England) 2003;17(7):1017-22.
2003: Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2003;47(2):594-600.
2003: Jade Ghosn; Claire Lamotte; Hocine Ait Mohand; Marc Wirden; Rachid Agher; Luminita Schneider; François Bricaire; Claudine Duvivier; Vincent Calvez; Gilles Peytavin; Christine Katlama
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
AIDS (London, England) 2003;17(2):209-14.
2003: Anne-Marie Taburet; Sabine Paci-Bonaventure; Gilles Peytavin; Jean-Michel Molina
Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies.
Clinical pharmacokinetics 2003;42(14):1179-91.
2002: Diane Descamps; Philippe Flandre; Véronique Joly; Vincent Meiffrédy; Gilles Peytavin; Jacques Izopet; Catherine Tamalet; Ai-Feng Zeng; Marine Harel; STEPHANE LASTERE; Jean-Pierre Aboulker; Patrick Yéni; Françoise Brun-Vézinet
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Journal of acquired immune deficiency syndromes (1999) 2002;31(5):464-71.
2002: Nicolas Dupin; Marc Buffet; Anne-Geneviève Marcelin; Claire Lamotte; Isabelle Gorin; Zaina Ait-Arkoub; Jean-Marc Tréluyer; Patrick Bui; Vincent Calvez; Gilles Peytavin
HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy.
AIDS (London, England) 2002;16(18):2419-24.
2002: Bernard Masquelier; Gilles Peytavin; Catherine Leport; Cecile Droz; Ségolène Duran; Renaud Verdon; Jean-Marc Besnier; Geneviève Chêne; François Raffi; Françoise Brun-Vézinet
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.
The Journal of infectious diseases 2002;186(10):1503-7.
2002: Beny Charbit; Laurent Becquemont; Bénédicte Lepère; Gilles Peytavin; Christian Funck-Brentano
Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine.
Clinical pharmacology and therapeutics 2002;72(5):514-23.
2002: Odile Launay; Laurence Gérard; Laurence Morand-Joubert; Philippe Flandre; Sonia Guiramand-Hugon; Véronique Joly; Gilles Peytavin; Agnès Certain; Claude Lévy; Stéphane Rivet; Christine Jacomet; Jean-Pierre Aboulker; Patrick Yéni
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2002;35(9):1096-105.
2002: Louis Bernard; Albert Vuagnat; Gilles Peytavin; Marie-Charlotte Hallouin; Damien Bouhour; Thu Huyen Nguyen; Jean-Louis Vildé; François Bricaire; Gilles Raguin; pierre de truchis; David Ghez; Michel Duong; Christian Perronne
Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy.
Annals of internal medicine 2002;137(8):656-9.
2002: Christophe Piketty; Gilles Peytavin; A Trylezinski; Gustavo Gonzalez-Canali; P Castiel; Laurence Weiss; Michel D Kazatchkine
Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.
HIV medicine 2002;3(4):287-9.
2002: Olivier Bouchaud; Fabrice Bruneel; Ricarda Schiemann; Gilles Peytavin; Jean-Pierre Coulaud
Severe cardiac toxicity due to halofantrine: importance of underlying heart disease.
Journal of travel medicine 2002;9(4):214-5.
2002: Philippe Flandre; Gilles Peytavin; Vincent Meiffredy; Yacine Saidi; Diane Descamps; Martine Delagnes; Françoise Brun-Vézinet; François Raffi
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Antiviral therapy 2002;7(2):113-21.
2002: Constance Delaugerre; Anne-Geneviève Marcelin; Vincent Thibault; Gilles Peytavin; Tony Bombled; Marie Bochet; Christine Katlama; Yves Benhamou; Vincent Calvez
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Antimicrobial agents and chemotherapy 2002;46(5):1586-8.
2002: Jean-Luc Meynard; Muriel Vray; Laurence Morand-Joubert; Ester Race; Diane Descamps; Gilles Peytavin; Sophie Matheron; Claire Lamotte; Sonia Guiramand; Dominique Costagliola; Françoise Brun-Vézinet; François Clavel; Pierre-Marie Girard
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.
AIDS (London, England) 2002;16(5):727-36.
2002: Philippe Flandre; François Raffi; Diane Descamps; Vincent Calvez; Gilles Peytavin; Vincent Meiffredy; Marine Harel; Sylvie Hazebrouck; Gilles Pialoux; Jean-Pierre Aboulker; Françoise Brun Vezinet
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
AIDS (London, England) 2002;16(4):561-8.
2002: Nader Bassilios; Vincent Launay-Vacher; Abdelaziz Hamani; Laurent Masias; Gilles Peytavin; Jean-Baptiste Fau; Gilbert Deray
Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2002;17(3):531-2.
2002: Xavier Duval; Claire Lamotte; Ester Race; Diane Descamps; Florence Damond; François Clavel; Catherine Leport; Gilles Peytavin; Jean-Louis Vilde
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
Antimicrobial agents and chemotherapy 2002;46(2):570-4.
2001: Michel Duong; Lionel Piroth; Gilles Peytavin; F Forte; Evelyne Kohli; Michèle Grappin; Marielle Buisson; Pascal Chavanet; Henri Portier
Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(3):386-92.
2001: I Gaou; M Malliti; Marie-Christine Guimont; Philippe Lettéron; Christine Demeilliers; Gilles Peytavin; Claude Degott; Dominique Pessayre; Bernard Fromenty
Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice.
The Journal of pharmacology and experimental therapeutics 2001;297(2):516-23.
2001: Michel Duong; Lionel Piroth; Michèle Grappin; F Forte; Gilles Peytavin; Marielle Buisson; Pascal Chavanet; Henri Portier
Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.
HIV clinical trials 2001;2(2):128-35.
2001: Laurent Mandelbrot; Gilles Peytavin; Ghislaine Firtion; Robert Farinotti
Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women.
American journal of obstetrics and gynecology 2001;184(2):153-8.
2000: Xavier Duval; Vincent Le Moing; C Longuet; Catherine Leport; Jean-Louis Vildé; Claire Lamotte; Gilles Peytavin; Robert Farinotti
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Antimicrobial agents and chemotherapy 2000;44(9):2593.
2000: Mireille Mouroux; A Yvon-Groussin; Gilles Peytavin; Constance Delaugerre; Mayeule Legrand; Philippe Bossi; B Do; A Trylesinski; B Diquet; E Dohin; Jean-François Delfraissy; Christine Katlama; Vincent Calvez
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.
Journal of clinical microbiology 2000;38(7):2726-30.
2000: Christophe Piketty; Ester Race; P Castiel; Laurent Belec; Gilles Peytavin; Ali Si-Mohamed; Gustavo Gonzalez-Canali; Laurence Weiss; François Clavel; Michel D Kazatchkine
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
AIDS (London, England) 2000;14(5):626-8.
2000: Diane Descamps; Philippe Flandre; Vincent Calvez; Gilles Peytavin; Vincent Meiffredy; Gilles Collin; Constance Delaugerre; S Robert-Delmas; B Bazin; Jean-Pierre Aboulker; Gilles Pialoux; François Raffi; Françoise Brun-Vézinet
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
JAMA : the journal of the American Medical Association 2000;283(2):205-11.
1999: Claire Lamotte; Gilles Peytavin; Robert Farinotti
Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):159-70.
1999: M Nascimbeni; Claire Lamotte; Gilles Peytavin; Robert Farinotti; François Clavel
Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.
Antimicrobial agents and chemotherapy 1999;43(11):2629-34.
1999: Christophe Piketty; Ester Race; P Castiel; Laurent Belec; Gilles Peytavin; Ali Si-Mohamed; Gustavo Gonzalez-Canali; Laurence Weiss; François Clavel; Michel D Kazatchkine
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
AIDS (London, England) 1999;13(11):F71-7.
1998: Louis Bernard; Gilles Peytavin; Albert Vuagnat; pierre de truchis; Christian Perronne
Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy.
Lancet 1998;352(9142):1757-8.